Compare Sana Biotechnology Inc (SANA) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Sana Biotechnology Inc trades at $3.2 (market cap $873.84M), while State Street Technology Select Sector SPDR ETF trades at $178.45. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | XLK | |
|---|---|---|
Market Cap | $873.84M | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $198.21 |
52-Week Low | $2.68 | $127.49 |
Enterprise Value | $848.03M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
XLK trades at $175.71 with minimal daily movement (+0.07%), showing technical bearish signals while maintaining strong year-to-date performance of 33%. The ETF's technical indicators show selling pressure with bearish moving averages, though oscillators remain neutral. Recent news highlights XLK as the top-performing sector SPDR in 2026, driven by technology sector strength and institutional inflows.
Outlook remains positive given technology sector momentum and strong earnings expectations, though concentration risk and technical weakness warrant monitoring. The ETF benefits from sector leadership but faces headwinds from potential Fed policy shifts and market volatility. Current levels near pivot point resistance at $176 suggest near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
